Healthcare
Neumora Therapeutics, Inc. Common Stock(NMRA)
Live Price
Offline$1.51
-1.31% today
1Y Change
+99.47%
Window
Jun 27, 2025 โ Jun 18, 2026
- Market Cap
- $450.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +5.2%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 27, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Neumora Therapeutics, Inc. Common Stock (NMRA) is a Healthcare stock with a market cap of $450.00M and listed on NASDAQ. The stock last traded around $1.51 and up 99.5% across the available one-year price window (Jun 27, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +5.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +5.2%, free cash flow -12.8% with operating margin 0.0% and ROIC -151.8%. Stock Foundry combines NMRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +5.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +1.6% | -5.3% | -11.8% |
2026 Mar 16, 2026 | -2.9% | -1.4% | -13.9% | -29.3% |
2025 Nov 6, 2025 | -2.9% | -0.8% | +4.3% | -14.0% |
Benchmark Edge
NMRA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NMRA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NMRA Max Drawdown
-74.51%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NMRA and SPY.
Company Overview
Neumora Therapeutics, Inc. Common Stock
NASDAQ Global Select
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
- Leadership
- Daljit Singh Aurora
- IPO Date
- Sep 15, 2023
- Employees
- 110
- Street Address
- 490 Arsenal Way
- Mailing
- Watertown, DE, 02472
- Region
- Watertown, DE, US
- Reporting Currency
- USD
- Investor Line
- 857 760 0900
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.8
Growth
- Revenue
- 0.0%
- EPS
- +5.2%
- Free Cash Flow
- -12.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -146.4%
- ROIC
- -151.8%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 5.87
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.